Psoriatic Arthritis

Acelyrin announced the positive results, of which the primary endpoint was met with high statistical significance, earlier this week.

Findings reveal an increased risk of psoriatic arthritis among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.

New evidence identifies factors that may predict which patients with psoriasis will develop psoriatic arthritis.

While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.

Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.

Investigators report 12 weeks of treatment provided a strong foundation for further evaluation of TAK-279 across the psoriatic arthritis disease spectrum.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

Apremilast is being examined for the treatment of psoriatic arthritis.

The phase 3b trial showed improvements to minimal disease activity in adults with the condition.

The JAK inhibitor demonstrated promising efficacy and safety.

The findings suggest a need to conduct cancer screening by a detailed history and comprehensive clinical examination in patients with PsA.

Researchers said the drug was also well-tolerated in patients.

A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA.

New pathways of care are needed to improve health care spending.

At the 2022 Fall Clinical Dermatology Conference, Bruce E. Strober, MD, PhD, reviewed the best treatment options for patients with psoriasis and psoriatic arthritis.

Two expert dermatologists discuss the relationship between PsA and PsO in this DermView series recap.

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

At the SDPA 2022 Annual Summer Dermatology Conference, a session on both common and rare dermatological disorders.

Tralokinumab-ldrm (Adbry; LEO Pharma) showed improvement in itch, sleep, anxiety, depression, and overall quality of life data for adolescent AD patients in newly released study data.

AbbVie announced the FDA approval to their IL-23 inhibitor risankizumab-rzaa (Skyrizi) for treatment of active psoriatic arthritis (PsA) in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

A recent study investigated apremilast use for psoriasis during COVID-19 infection.

The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.

The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.

Amgen and the International Federation of Psoriasis Associations have announced their efforts to combat the challenges of psoriasis.

Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.